JPRN-UMIN000006414
Completed
未知
A pilot study of heat immunotherapy using cationic magnetoliposome for advanced melanoma patients - combined therapy with topical imiquimod immunotherapy - Combination of heat immunotherapy and topical imiquimod immunotherapy for adavanced melanoma patients
Department of Dermatology, Shinshu University School of Medicine0 sites5 target enrollmentOctober 1, 2011
Conditionsmelanoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- melanoma
- Sponsor
- Department of Dermatology, Shinshu University School of Medicine
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The trial was terminated.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. An anti\-ancer therapy has been recieved within previoous 4 weeks 2\. Patients who have brain matastases 3\. Patients who have a life expectancy of less than 6 months 4\. Patients who are pregnant or nursing 5\. Patients who have severe pleural or pericardial effusion or ascites 6\. Patients who have active infection 7\. Patients who have other malignancies 8\. Patients who are unable to keep protocol due to psychiatric, familial, social or traffic disadvantage 9\. Patients who have metals inside the body near (within 10 cm) the lesion where alternative magnetic field is put 10\. Patients who have active asthma, or have had severe anaphilaxis before 11\. Patients who are judged inappropriate to be enrolled in this study by clinical investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II clinical trial of Carbon-ion therapy for patients with bone and soft tissue sarcomas not suited for surgical resectioBone and soft tissue tumorJPRN-UMIN000021557Kanagawa Cancer Center, Kanagawa Prefectural Hospital Organization
Completed
Not Applicable
COVIPLA-RCOVID-19, Coronavirus diseaseCOVID-19, coronavirus disease, SARS-CoV-2, 2019-nCoVC000657245JPRN-jRCTs031200124Saito Sho11
Completed
Phase 2
A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinomagastric cancerJPRN-UMIN000003201Study group of multi-modality therapy for gastric cancer5
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190100Takimoto Rishu40
Completed
Phase 2
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190098Takimoto Rishu40